Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
J Clin Biochem Nutr ; 72(1): 13-22, 2023 Jan.
Article in English | MEDLINE | ID: mdl-36777080

ABSTRACT

Although many diseases in which reactive oxygen species (ROS) and free radicals are involved in their pathogenesis are known, and antioxidants that effectively capture ROS have been identified and developed, there are only a few diseases for which antioxidants have been used for treatment. Here, we discuss on the following four concepts regarding the development of applications for disease treatment by regulating ROS, free radicals, and lipid oxidation with the findings of our research and previous reports. Concept 1) Utilization of antioxidants for disease treatment. In particular, the importance of the timing of starting antioxidant will be discussed. Concept 2) Therapeutic strategies using ROS and free radicals. Methods of inducing ferroptosis, which has been advocated as an iron-dependent cell death, are mentioned. Concept 3) Treatment with drugs that inhibit the synthesis of lipid mediators. In addition to the reduction of inflammatory lipid mediators by inhibiting cyclooxygenase and leukotriene synthesis, we will introduce the possibility of disease treatment with lipoxygenase inhibitors. Concept 4) Disease treatment by inducing the production of useful lipid mediators for disease control. We describe the treatment of inflammatory diseases utilizing pro-resolving mediators and propose potential compounds that activate lipoxygenase to produce these beneficial mediators.

2.
Rev. bras. ginecol. obstet ; 44(3): 304-310, Mar. 2022. tab, graf
Article in English | LILACS | ID: biblio-1387875

ABSTRACT

Abstract Objective To review data on the use of corticosteroids for the treatment of fetuses with high-risk congenital pulmonary adenomatoid malformation (CPAM). Methods Integrative review based on the literature available onMEDLINE and LILACS, including articles published until November, 2020. Results The initial search resulted in 87 articles, 4 of which were selected for analysis, with all of them being retrospective descriptive observational studies. In the group of fetuses that received only a single corticosteroid cycle, the hydrops resolution rate was 70%, and the survival rate was 83.8%. In fetuses treated with 2 or more cycles of corticosteroids, there was an improvement in the condition of hydrops or edema in a single body compartment in 47%, and survival of 81.8% of the fetuses. Conclusion The use of corticosteroids for the prenatal treatment of high-risk CPAM appears to be associated with an improvement in perinatal outcomes.


Resumo Objetivo Revisar os dados sobre o uso de corticoide no tratamento de fetos com malformação adenomatoide pulmonar congênita (MAPC) de alto risco. Métodos Revisão integrativa com base na literatura disponível no MEDLINE e LILACS, incluindo artigos publicados até novembro de 2020. Resultados A busca inicial resultou em 87 artigos, dos quais 4 foram selecionados para análise, todos tratando-se de estudos observacionais descritivos retrospectivos. No grupo de fetos que recebeu apenas um único ciclo de corticosteroide, a taxa de resolução da hidropsia foi de 70% e a taxa de sobrevida de 83,8%. Emfetos tratados com 2 ou mais ciclos de corticosteroides, houve melhora do quadro de hidropsia ou edema em um único compartimento corporal em 47% dos fetos e taxa de sobrevida de 81,8%. Conclusão O uso de corticosteroides para o tratamento pré-natal da MAPC de alto risco parece estar associado à melhora dos resultados perinatais.


Subject(s)
Humans , Female , Pregnancy , Betamethasone , Cystic Adenomatoid Malformation of Lung, Congenital , Adrenal Cortex Hormones , Edema , Fetus/abnormalities
3.
J Matern Fetal Neonatal Med ; 35(20): 4004-4008, 2022 Oct.
Article in English | MEDLINE | ID: mdl-33143511

ABSTRACT

BACKGROUND/OBJECTIVE: Currently, there is no validated treatment for fetal cytomegalovirus (CMV). Two studies suggest that high-dose maternal valacyclovir decreases fetal viral load and improves outcomes in moderately-symptomatic fetuses. We offered valacyclovir in cases of fetal infection lacking ultrasound abnormalities or with non-severe infection. Maternal tolerability, fetal outcome and newborn blood viral load were evaluated in pregnancies of mothers receiving valacyclovir. STUDY DESIGN: We performed a case series including 8 pregnancies with fetal CMV classified as unaffected/mildly-moderately affected. Mothers received valacyclovir (8 g/24h) from fetal infection diagnosis to delivery. Standard newborn evaluation was performed, and viremia was determined in the first 48 h of life and compared according to length of maternal treatment and presence/absence of prenatal anomalies. RESULTS: Valacyclovir was administered at a median gestational age of 26.5 weeks (23.8-33.1) in 3 cases without fetal abnormalities, and 5 with mild/moderate abnormalities. Three were 3 first trimester primary infections, one non-primary infection, and in 4 the type of infection was unknown. Valacyclovir was well-tolerated. Fetal features did not progress. Three newborns were asymptomatic, and one was severely affected (bilateral chorioretinitis). The median newborn viral load (IQR) was 502 IU/mL (231-191781) with lower levels when maternal treatment was administered ≥10 weeks, and in cases without fetal abnormalities [median 234 IU/mL (228-711) vs. 4061 (292-510500) p = .18; and 234 IU/mL (228-379500) vs. 711 IU/mL (292-4061) p = .65, respectively], these differences being non-significant. CONCLUSIONS: Fetal CMV lesions remained stable with high-dose maternal valacyclovir. Newborn viral load was unchanged despite treatment duration and fetal/neonatal abnormalities. SUMMARY: Fetal cytomegalovirus lesions remained stable with high-dose maternal valacyclovir. Newborn viral load was unchanged despite treatment duration and fetal/newborn abnormalities.


Subject(s)
Cytomegalovirus Infections , Fetal Diseases , Pregnancy Complications, Infectious , Cytomegalovirus , Cytomegalovirus Infections/diagnosis , Female , Fetal Diseases/diagnosis , Humans , Infant , Infant, Newborn , Infectious Disease Transmission, Vertical , Pregnancy , Pregnancy Complications, Infectious/diagnosis , Valacyclovir/therapeutic use , Viral Load
4.
Stem Cell Rev Rep ; 18(2): 752-767, 2022 02.
Article in English | MEDLINE | ID: mdl-33742349

ABSTRACT

Neural tube defects (NTDs) are among the most common congenital defects during neurulation. Spina bifida is a type of NTD that can occur in different forms. Since myelomeningocele (MMC) is the most severe form of spina bifida, finding a satisfactory treatment for MMC is a gold standard for the treatment of spina bifida. The Management of Myelomeningocele Study (MOMS) demonstrated that intrauterine treatment of spina bifida could ameliorate the complications associated with spina bifida and would also reduce the placement of ventriculoperitoneal (VP) shunt by 50%. Recently developed tissue engineering (TE) approaches using scaffolds, stem cells, and growth factors allow treatment of the fetus with minimally invasive methods and promising outcomes. The application of novel patches with appropriate stem cells and growth factors leads to better coverage of the defect with fewer complications. These approaches with less invasive surgical procedures, even in animal models with similar characteristics as the human MMC defect, paves the way for the modern application of less invasive surgical methods. Significantly, the early detection of these problems and applying these approaches can increase the potential efficacy of MMC treatment with fewer complications. However, further studies should be conducted to find the most suitable scaffolds and stem cells, and their application should be evaluated in animal models. This review intends to discuss advanced TE methods for treating MMC and recent successes in increasing the efficacy of the treatment.


Subject(s)
Meningomyelocele , Spinal Dysraphism , Animals , Female , Meningomyelocele/complications , Meningomyelocele/diagnosis , Meningomyelocele/therapy , Neural Tube , Pregnancy , Spinal Dysraphism/therapy , Stem Cell Transplantation , Tissue Engineering
5.
J Obstet Gynecol Neonatal Nurs ; 49(3): 254-262, 2020 05.
Article in English | MEDLINE | ID: mdl-32109429

ABSTRACT

OBJECTIVE: To synthesize nursing practices related to fetal therapy (intervention to correct or treat a fetal anomaly). DATA SOURCES: We searched electronic databases, including PubMed, Embase, OvidSP, and CINAHL, for all relevant published work. We identified additional resources through discussion with experts in the field, hand searches of relevant resources, and examination of the reference lists of articles in our search results. STUDY SELECTION: Any published literature about fetal therapy in which nursing practices were discussed by nurses. DATA EXTRACTION: We used Whittemore and Knafl's methodology to guide this integrative review (2005). We completed data extraction using an analytic review template organized to compare results to Kim's (2015) theoretical framework for nursing practice. DATA SYNTHESIS: We used qualitative techniques described by Miles, Huberman, and Saldaña (2014) to code and thematically interpret the data. Nurses described their contributions to the establishment of fetal therapy programs through the development of entirely new technical and caring skills and their work in relation to care quality, clinician education, ethics, research, and health policy. Data were synthesized under three philosophies of nursing practice: therapy, care, and professional work. CONCLUSION: Nurses have made important contributions to the evolving practice of fetal therapy, a nuanced practice that is critical to the development and provision of comprehensive patient- and family-centered care. Clinical implications of this review include practical recommendations for enhanced support of nursing practice in fetal therapy, which includes the provision of reliable forums to learn and share feedback about nursing practice in this field. Future work should focus on increasing understanding and visibility of nursing in fetal therapy through interdisciplinary evidence-based practice development.


Subject(s)
Fetal Therapies/nursing , Nursing Care/methods , Fetal Therapies/trends , Fetus/physiology , Fetus/physiopathology , Humans
6.
Dev Period Med ; 22(3): 229-237, 2018.
Article in English | MEDLINE | ID: mdl-30281518

ABSTRACT

The article underlined the role of perinatal cardiology in contributing to the medical care of the pregnant woman taking into consideration the technical and medical progress which has made it possible to save not only human life but also its quality. The role of correct early diagnosis, as well as correct treatment was discussed and the results of such procedure demonstrated.


Subject(s)
Heart Defects, Congenital/diagnosis , Pregnancy Complications, Cardiovascular/diagnosis , Cardiac Surgical Procedures , Early Diagnosis , Female , Heart Defects, Congenital/surgery , Humans , Infant, Newborn , Male , Pregnancy , Pregnancy Complications, Cardiovascular/surgery , Treatment Outcome
8.
Semin Perinatol ; 40(4): 227-33, 2016 06.
Article in English | MEDLINE | ID: mdl-26804036

ABSTRACT

This article explores some of the complex ethical challenges that exist in the field of fetal diagnosis and treatment, especially surrounding maternal-fetal surgery. The rise of these new treatments force us to reconsider who or what is the fetus, what are our obligations to the fetus, and what are the limits to those obligations. In addition, we will consider provider and professional biases, disability issues, and how maternal-fetal surgery has, for a select group of women, changed the very experience of motherhood.


Subject(s)
Beginning of Human Life/ethics , Ethics, Medical , Fetal Diseases/surgery , Informed Consent/ethics , Maternal-Fetal Relations/psychology , Pregnant Women , Female , Fetal Diseases/psychology , Fetal Viability/physiology , Humans , Informed Consent/psychology , Moral Obligations , Personal Autonomy , Personhood , Pregnancy , Pregnant Women/psychology , Risk Assessment
9.
Fetal Pediatr Pathol ; 34(1): 1-8, 2015 Feb.
Article in English | MEDLINE | ID: mdl-24941233

ABSTRACT

We report a case of a giant placental chorioangioma (15.6 cm diameter) complicated by polyhydramnios and severe fetal heart failure. Fetoscopic laser occlusion of a dominant feeding vessel was performed at 29 weeks' gestation and partial devascularization was achieved. In the 33rd week of the pregnancy, the decision was made to preemptively deliver the fetus due to persistent signs of fetal cardiac failure. After birth, the infant developed multifocal infantile hemangiomas with extracutaneous involvement. We posit that the development of infantile hemangiomas may be linked to the presence of the large chorioangioma. Further study is required to ascertain if fetal treatment of the chorioangioma may have been an exacerbating factor.


Subject(s)
Heart Failure/embryology , Heart Failure/therapy , Hemangioma/diagnosis , Hemangioma/therapy , Placenta Diseases/diagnosis , Placenta Diseases/therapy , Polyhydramnios/diagnosis , Polyhydramnios/therapy , Adult , Female , Fetoscopy , Heart Failure/complications , Hemangioma/complications , Hemangioma/embryology , Humans , Infant, Newborn , Lasers , Male , Pregnancy , Pregnancy Complications, Neoplastic , Pregnancy Outcome , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...